BioLife 解决方案

US · BLFS #2844 按市值排名上市于 1970

38.61 0.00 0.00%

实时 - 追踪5344个代码 - 心跳于421秒前 · 2026-10-15 19:54

✦ 量化股权信号计算方式说明

减持

最近一期（2026/Q3）披露持股的机构数量增加了7家。
机构持股总比例下降了0.4个百分点。

机构持股

机构持股比例: 101.73% -0.38pp
机构数量: 264 +7
数据截至: 2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund74.49%

Hedge Fund10.48%

VC/PE Fund9.52%

Public Company3.07%

Individual/Insider2.93%

Government Pension Fund1.53%

Private Company1.15%

Insurance Company1.10%

Sovereign Wealth Fund0.31%

主要股东截至 2026-06-30

BlackRock 13.04% · 6.38M 股

Casdin Capital, LLC 9.52% · 4.66M 股

T. Rowe Price Group, Inc. 7.50% · 3.67M 股

Glazer Capital, LLC 5.49% · 2.69M 股

Vanguard Capital Management, LLC 4.57% · 2.24M 股

Invesco Ltd. 4.45% · 2.18M 股

State Street Global Advisors 3.39% · 1.66M 股

Geode Capital Management, LLC 2.22% · 1.09M 股

MFS Investment Management 2.21% · 1.08M 股

Fred Alger Management, LLC 2.20% · 1.08M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 5次买入 · 45次卖出

姓名	职务	持股比例
Roderick de Greef	Director	0.85%
Aby Mathew	Chairman of Scientific Advisory Board, Executive VP & Chief Scientific Officer	0.79%
Troy Wichterman	Chief Financial Officer	0.43%
Todd Berard	Chief Marketing Officer	0.33%
Rachel Ellingson	Independent Director	0.12%
Joydeep Goswami	Independent Director	0.11%
Sean Werner	Chief Technology Officer	0.10%
Timothy Moore	Independent Director	0.09%
Amy DuRoss	Independent Director	0.05%
Anthony Hunt	Director	0.03%

内部人交易最近的 Form 4 申报记录

日期	姓名	职务	类型	股数	价格
2026-09-17	Roderick de Greef	Director	Sale to Issuer	-2,775	$36.69
2026-09-17	Aby Mathew	Chairman of Scientific Advisory Board, Executive VP & Chief Scientific Officer	Sale to Issuer	-564	$36.69
2026-09-17	Todd Berard	Chief Marketing Officer	Sale to Issuer	-470	$36.69
2026-09-17	Troy Wichterman	Chief Financial Officer	Sale to Issuer	-937	$36.69
2026-09-17	Sean Werner	Chief Technology Officer	Sale to Issuer	-421	$36.69
2026-09-07	Aby Mathew	Chairman of Scientific Advisory Board, Executive VP & Chief Scientific Officer	Sale to Issuer	-627	$35.38
2026-09-07	Todd Berard	Chief Marketing Officer	Sale to Issuer	-356	$35.38
2026-09-07	Troy Wichterman	Chief Financial Officer	Sale to Issuer	-1,026	$35.38
2026-07-16	Sean Werner	Chief Technology Officer	Sale to Issuer	-275	$29.15
2026-07-06	Aby Mathew	Chairman of Scientific Advisory Board, Executive VP & Chief Scientific Officer	Sale to Issuer	-516	$27.79
2026-07-06	Todd Berard	Chief Marketing Officer	Sale to Issuer	-293	$27.79
2026-07-06	Troy Wichterman	Chief Financial Officer	Sale to Issuer	-844	$27.79
2026-06-17	Roderick de Greef	Director	Sale to Issuer	-2,775	$26.04
2026-06-17	Aby Mathew	Chairman of Scientific Advisory Board, Executive VP & Chief Scientific Officer	Sale to Issuer	-564	$26.04
2026-06-17	Todd Berard	Chief Marketing Officer	Sale to Issuer	-470	$26.04
2026-06-17	Troy Wichterman	Chief Financial Officer	Sale to Issuer	-937	$26.04
2026-06-17	Sean Werner	Chief Technology Officer	Sale to Issuer	-420	$26.04
2026-06-07	Aby Mathew	Chairman of Scientific Advisory Board, Executive VP & Chief Scientific Officer	Sale to Issuer	-627	$26.10
2026-06-07	Todd Berard	Chief Marketing Officer	Sale to Issuer	-356	$26.10
2026-06-07	Troy Wichterman	Chief Financial Officer	Sale to Issuer	-1,026	$26.10

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-15 19:54:59 · 仅供参考，不构成投资建议，也未考虑您的具体情况。